ArticleComprehensive Physiology2026
Inactivation of the Phosphatase Activity of Soluble Epoxide Hydrolase Modulates SIRT3 and Attenuates Experimental Pulmonary Hypertension.
Article in Comprehensive Physiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
introductionPulmonary hypertension (PH) is a severe cardiovascular disorder characterized by elevated pulmonary artery pressure caused by remodeling of the pulmonary circulation. This study aimed to investigate the role of the soluble epoxide hydrolase phosphatase domain (sEH-P) in PH pathogenesis.
methodsThe effects of sEH-P genetic inactivation were evaluated in vivo using a CRISPR/Cas9-mediated approach in two rat modes of PH: the monocrotaline and the Sugen/hypoxia model. To further explore the underlying mechanisms, complementary in vitro experiments were conducted in cultured human pulmonary artery smooth muscle cells (PA-SMCs), where sEH expression was modulated.
resultssEH-P inactivation attenuated experimental PH in both rat models, as demonstrated by reductions in mean pulmonary artery pressure and total pulmonary vascular resistance. Histological analysis showed decreased pulmonary artery muscularization and reduced collagen deposition in the right ventricle. Moreover, sEH-P inactivation reduced sEH protein levels and enhanced SIRT3 expression in the lungs. Two-hybrid interaction assays suggested that sEH indirectly regulates SIRT3 expression. In cultured human PA-SMCs, altering sEH levels influenced SIRT3 expression, cell proliferation, and the levels of FoxO1, BCL2, and Bax proteins. In sEH-P KI rat lungs, FoxO1 levels increased, while anti-apoptotic BCL2 protein decreased.
conclusionsOur findings underscore the role of sEH-P in the development and progression of PH, partly through its regulation of SIRT3 expression, cell proliferation, and apoptosis-related proteins. Targeting sEH-P emerges as a promising therapeutic strategy for PH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.